Literature DB >> 30878128

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.

Gina Rosas1, Rossana Ruiz2, Jhajaira M Araujo3, Joseph A Pinto3, Luis Mas4.   

Abstract

The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein rearranged in 2-7% of non-small cell lung cancer (NSCLC) cases. This gene has become the second most studied therapeutic target after EGFR due to the implied therapeutic opportunities. While the diagnostic of ALK rearrangements is well established, small molecules targeting ALK are in constant evolution because tumor cells eventually will develop mechanisms of resistance. In this review we describe the biology of the ALK gene, alterations, epidemiology, diagnostic tests as well as strategies of treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALK; Diagnostic tests; Non-small cell lung cancer; Tyrosine-kinase inhibitors

Mesh：

Substances：

Year:  2019        PMID： 30878128     DOI： 10.1016/j.critrevonc.2019.02.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  11 in total

1.  PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2019-07-15       Impact factor: 4.345

Review 2.  Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire.

Authors:  Sebastian P Haen; Markus W Löffler; Hans-Georg Rammensee; Peter Brossart
Journal:  Nat Rev Clin Oncol       Date:  2020-06-22       Impact factor: 66.675

3.  The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.

Authors:  Nele Van Der Steen; Karen Zwaenepoel; Giulia Mazzaschi; Rosa A Luirink; Daan P Geerke; Ken Op de Beeck; Christophe Hermans; Marcello Tiseo; Paul Van Schil; Filip Lardon; Paul Germonpré; Christian Rolfo; Elisa Giovannetti; Godefridus J Peters; Patrick Pauwels
Journal:  Molecules       Date:  2019-12-04       Impact factor: 4.411

Review 4.  Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.

Authors:  Paul Hofman
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

5.  Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report.

Authors:  Gang Shen; Yinping Du; Jifang Shen; Junling Zhang; Xihua Xia; Mengli Huang; Wenxiang Shen
Journal:  Onco Targets Ther       Date:  2021-12-23       Impact factor: 4.147

6.  Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.

Authors:  Sergey V Orlov; Aglaya G Iyevleva; Elena A Filippova; Alexandra M Lozhkina; Svetlana V Odintsova; Tatiana N Sokolova; Natalia V Mitiushkina; Vladislav I Tiurin; Elena V Preobrazhenskaya; Alexandr A Romanko; Alexandr S Martianov; Alexandr O Ivantsov; Svetlana N Aleksakhina; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Transl Oncol       Date:  2021-05-21       Impact factor: 4.243

Review 7.  Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.

Authors:  Maria Walls; Gerard M Walls; Jacqueline A James; Kyle T Crawford; Hossam Abdulkhalek; Tom B Lynch; Aaron J Peace; Terry E McManus; O Rhun Evans
Journal:  BMC Pulm Med       Date:  2020-08-06       Impact factor: 3.317

8.  Functional and clinical significance of ROR1 in lung adenocarcinoma.

Authors:  Giovanna Schiavone; Samantha Epistolio; Vittoria Martin; Francesca Molinari; Jessica Barizzi; Luca Mazzucchelli; Milo Frattini; Luciano Wannesson
Journal:  BMC Cancer       Date:  2020-11-10       Impact factor: 4.430

9.  Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.

Authors:  Gernot Wagner; Hannah Karolina Stollenwerk; Irma Klerings; Martin Pecherstorfer; Gerald Gartlehner; Josef Singer
Journal:  Oncoimmunology       Date:  2020-06-16       Impact factor: 8.110

Review 10.  An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.

Authors:  Adela Patcas; Ana Florica Chis; Claudia Florentina Militaru; Ioana Roxana Bordea; Ruxandra Rajnoveanu; Ovidiu Florin Coza; Reem Hanna; Tamas Tiberiu; Doina Adina Todea
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.